The importance of the Covid-19 vaccine in patients suffering from adult autosomal dominant polycystic kidney disease (ADPKD)
DOI:
https://doi.org/10.33393/gcnd.2021.2256Keywords:
ADPKD patients, SARS-CoV-2 (Covid-19), VaccineAbstract
The SARS-CoV-2 (Covid-19) infection affected about 106 million people worldwide and the total amount of casualties now sits at a staggering 2 millions.
Chronic Kidney Disease (CKD) emerged as the first risk factor in worst patients, not considering old age. Kidney disease and acute kidney injury have been correlated with a higher chance of death. This combination of CKD and higher Covid-19 related mortality requires immediate response from a prevention point of view at first and then from a therapeutic one.
There is not a clear relation between Covid-19 and ADPKD. What can be inferred is the following: Covid uses the ACE2 receptors on cell membranes to “lock on” its target. It is well-established in fact that the RAAS is more active in ADPKD patients and it may represent an additional risk factor for these patients.
At the moment three Covid-19 vaccines have been approved, and two of them have been already administered, such as Pfizer BioNTech and Moderna, sharing the same mechanism. AstraZeneca released a third option. All of them are completely safe and reliable, each one with its own feature.
Therefore, considering how delicate ADPKD patients are, vaccination is strongly recommended.
References
- Rashedi J, Mahdavi Poor B, Asgharzadeh V, et al. Risk Factors for COVID-19. Infez Med. 2020;28(4):469-474. PMID:33257620
- Adapa S, Chenna A, Balla M, et al. COVID-19 pandemic causing acute kidney injury and impact on patients with chronic kidney disease and renal transplantation. J Clin Med Res. 2020;12(6):352-361. https://doi.org/10.14740/jocmr4200 PMID: 32587651
- Gagliardi I, Patella G, Michael A, Serra R, Provenzano M, Andreucci M. COVID-19 and the kidney: from epidemiology to clinical practice. J Clin Med. 2020;9(8):2506. Online https://doi.org/10.3390/jcm9082506 PMID: 32759645
- Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-637. https://doi.org/10.1002/path.1570 PMID:15141377
- Stephens JR, Stümpfle R, Patel P, et al. Analysis of Critical Care Severity of Illness Scoring Systems in Patients With Coronavirus Disease 2019: A Retrospective Analysis of Three U.K. ICUs. Crit Care Med. 2021;49(1):e105-e107. https://doi.org/10.1097/CCM.0000000000004674PMID:32991357
- Fominskiy EV, Scandroglio AM, Monti G, et al; COVID-BioB Study Group. Prevalence, Characteristics, Risk Factors, and Outcomes of Invasively Ventilated COVID-19 Patients with Acute Kidney Injury and Renal Replacement Therapy. Blood Purif. 2021;50(1):102-109. https://doi.org/10.1159/000508657 PMID:32659757
- Quintaliani G, Reboldi G, Di Napoli A, et al; Italian Society of Nephrology COVID-19 Research Group. Exposure to novel coronavirus in patients on renal replacement therapy during the exponential phase of COVID-19 pandemic: survey of the Italian Society of Nephrology. J Nephrol. 2020;33(4):725-736. https://doi.org/10.1007/s40620-020-00794-1 PMID:32621109
- Sciarrone Alibrandi MT, Vespa M. Kidney, ADPKD and Covid-19: the double role of renal fragility. G Clin Nefrol E Dialisi. 2020;32(1):99-101. https://doi.org/10.33393/gcnd.2020.2165
- Polack FP, Thomas SJ, Kitchin N, et al; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615. https://doi.org/10.1056/NEJMoa2034577 PMID:33301246
- Anderson EJ, Rouphael NG, Widge AT, et al; mRNA-1273 Study Group. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020;383(25):2427-2438. https://doi.org/10.1056/NEJMoa2028436 PMID:32991794
- Glanville D. COVID-19 vaccines: key facts. European Medicines Agency. 2020. Online https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines-key-facts
- Vaccini a mRNA | Agenzia Italiana del Farmaco. Online https://aifa.gov.it/vaccini-mrna
- Vaccini a vettore virale | Agenzia Italiana del Farmaco. Online https://aifa.gov.it/vaccini-vettore-virale
- Glanville D. EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU. European Medicines Agency. 2021. Online https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu
- Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for Covid-19. Front Immunol. 2020;11:585354. Online https://www.frontiersin.org/articles/10.3389/fimmu.2020.585354/full
- Pinho AC. EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU. European Medicines Agency. 2021. Online https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu
- Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72-74. https://doi.org/10.1016/S0140-6736(20)32623-4 PMID:33306990
- Voysey M, Clemens SAC, Madhi SA, et al; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111. https://doi.org/10.1016/S0140-6736(20)32661-1 PMID:33306989